Language Scientific

Are Sub-Saharan African languages about to boom? French media network TV5MONDE recently announced two new subtitle languages: Swahili and Lingala, making its content accessible to 200 million people in Africa. A good reminder: localization isn’t just Spanish, French, and German. Many African languages are underrepresented in digital databases, the backbone of training material for translation memory and machine translation systems. This subtitling initiative shows that things are changing, and language access can’t stop at the “big” languages. Media may be leading the way, and clinical trials need to follow. Recruitment, consent, and outcome documents depend on language that patients and local clinicians understand. AI may accelerate the demand, but it doesn’t replace expertise. Especially in medical, scientific, and technical contexts, raw AI output still needs to be reviewed by subject-matter experts, especially in these languages with smaller training databases. For those of you working with Swahili, Lingala, Amharic, Yoruba, what are you seeing? 

The most dangerous AI translation errors? Those that sound completely fluent. AI-generated medical, scientific, and technical translations often sound great! Until you dig in, and notice: -Inconsistencies:  translation uses three different terms for the English word “pain” -Errors: AI engine doesn’t understand the English word “dropperful,” and leaves it as is or makes something up -Confusion: mixing up homophones like “ilium” and “ileum” AI can speed things up, but it’s like an eager-to-please employee whose work is fast, enthusiastic…and in need of a thorough review. Have you noticed these kinds of issues in unreviewed AI output?

Pharmacy automation shouldn’t leave LEP patients behind We’re seeing a lot of news items about pharmacy automation: robotic prescription-fillers, AI chatbots for patient communication. No doubt, pharmacies are struggling. All 50 U.S. states contain at least one “pharmacy desert,” predominantly in rural and marginalized communities. Automation can improve pharmacy access, but it can also widen language access gaps. Especially for patients with limited English proficiency (LEP), we need to be asking “Can the patient understand how to take this medication?” not just “How fast can we fill this prescription?” Not all “automated” translation is the same. Prescription translations from our subsidiary, RxTran, are automated for speed and consistency, *and* the content is validated by bilingual pharmacists and specialized medical translators. Pharmacy automation isn’t just a convenience feature; it needs clinical review, auditable quality processes, and professional liability insurance. If your pharmacy automation strategy includes LEP patients, we’re here to help with safety, clarity, and compliance. https://lnkd.in/gcjPwAhN #PharmacyTranslations #LEP #LanguageAccess #LanguageScientific 

How can pharmacies reduce risk, boost adherence, and attract more customers? Translated prescription labels do all three. “Doesn’t AI do that now? It’s just a few words!” Automated translation has come a long way, but raw AI output is simply too risky. It’s also a potential violation of state laws (in California, New York, Nevada, Oregon, pending in Washington), and Title VI of the Civil Rights Act. Additionally, AI struggles with non-standard words used in dosing instructions (“dropperful”). With some 25 million Americans having Limited English Proficiency, AI-translated prescription labels just aren’t worth the risk. Language Scientific’s subsidiary RxTran offers a better way, at an affordable cost, using an insurance-backed SaaS solution that integrates into your existing pharmacy management system. Full story on our blog: https://lnkd.in/g9G6xJsZ #PrescriptionLabelTranslation #LEP #PharmacyTranslation #RxTran

Poll: Questions about AI in the translation workflow If your organization uses medical, scientific, or technical translations, what’s your biggest question about using AI in the translation workflow? Vote below: We'd love to respond to these in a future post.

Duplicate files: A million-dollar error, until we spotted it Frustrated with late deliveries by their previous translation provider, ACI Clinical turned to Language Scientific, trusting us with 24-48 hour turnaround of their clinical trial documents. We immediately noticed an issue: submissions from their global trial sites often included pages they’d previously paid to translate, sometimes several years before. Language Scientific developed a proprietary process to check for duplicates.  This saved over $1 million in unnecessary translations by identifying these files before they made it into the translation workflow. You’ll get these kinds of results only from a translation company that operates at a human scale. Before we start translating, we ask the million-dollar questions. Read the full story on our website: https://lnkd.in/gmFh43-r #MedicalTranslation #ClinicalTranslation #LanguageScientific #ClinicalTrials 

Are you ready for the EU AI Act? More importantly, is your translation provider ready? The EU AI Act has been progressively implemented since 2024, and new provisions take effect on August 2 of this year. Issues that should be on your radar screen: -Verifiable metrics for human oversight. The Act requires documentation that qualified humans are reviewing and correcting automated translation output. -Overlap between the Act and the General Data Protection Regulation (GDPR). Public AI engines often contain personally identifiable information, and they don’t disclose the origins of their training data. -Explainable frameworks: Translation providers need to justify the choices that their AI translation tool makes. -Regulatory threats: Raw AI output is no longer just a quality issue, it’s a potential regulatory violation. A human must be accountable for the translation, and an auditable trail must document this. Language Scientific bridges the gap between AI efficiency and clinical precision. We’re the first and only translation company using a dual-review process to certify AI-generated translations, and we know that “good enough” is a liability.

IVDD to IVDR: One letter, big impact If you’re responsible for regulatory translations, the European Union’s transition from the In Vitro Medical Device Directive (IVDD) to the new Regulation (IVDR) is a big shift. Key takeaways: -Increased focus on risk: instead of being on a list of diseases/pathogens, devices are now Class A through D -Greater regulatory scrutiny: Many devices previously in the low-risk “Other” category have now been bumped up -Notified bodies: These designated organizations assess the compliance of certain products; no approval without their approval -Safety benefits and operational hurdles: Diagnostics have become more important, and the IVDR seeks to improve public health and safety. The challenge? Bringing existing devices into compliance while maintaining a supply of finished products. It’s a complex transition; get our expertise on your side. Learn more in our blog post:  https://lnkd.in/eYd-8YXR #IVDR #RegulatoryTranslation #LanguageScientific #InVitroDiagnostics

Color, or colour? Does it matter? You need a translation partner who knows the difference. In clinical translation, we usually think of big leaps between languages: from English into Chinese, Swahili, or Tagalog. But there can be real cultural and linguistic differences between US and UK English, or Brazilian and European Portuguese. The catch? Sometimes these (seemingly) small differences matter, and sometimes they don’t. Knowing which is which is where the real expertise comes in. When you’re translating an informed consent form, “small” differences in terminology, tone, or health literacy expectations can affect understanding and trust. But when you’re translating a highly technical protocol, over-localizing every regional preference can create unnecessary complexity, cost, and inconsistency. That’s where Language Scientific’s industry-leading expertise makes the difference: knowing when regional adaptation improves clarity, and when it just adds noise. #LinguisticValidation #LanguageScientific #MedicalTranslation #ScientificTranslation #ClinicalTranslation

Burmese prescription translation demand surges by 300% A Q1 2026 analysis of our subsidiary RxTran's proprietary data shows a significant shift in U.S. pharmacy care for the LEP (Limited English Proficiency) population. Demand for Asian and Middle Eastern languages has risen sharply since Q1 2025, while demand for several major European languages has declined. Requests for Pashto increased by 60% year over year, Farsi by 52%, and Vietnamese by 49%. By contrast, French requests fell by 20% over the same period. Our CEO Sharon Blank notes: "As the U.S. Limited English Proficiency (LEP) population continues to grow and diversify, pharmacies that rely on static language coverage are leaving patients behind and exposing themselves to compliance risk. RxTran’s proprietary data gives the pharmacy industry an early signal of where those gaps are opening, so that they can act before a patient is harmed or a regulator takes notice." Details in the sixth installment of RxTran's proprietary data series: https://lnkd.in/eGK6_4Wu #PrescriptionTranslation #LEP #RxTran #LanguageScientific #LanguageAccess